Significant Issues Derived from the Choice of a PSA Test for Measuring PSA in Serum: Comparison of IMx Enzyme immunoassay and ELSA Immunoradiometric Assay.
- Author:
Dal Bong HA
1
;
Chun Il KIM
;
Dong Seok JEON
;
Sung Choon LEE
Author Information
1. Department of Urology, Keimyung University, School of Medicine, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
Prostate cancer;
Prostate specific antigen
- MeSH:
Bias (Epidemiology);
Humans;
Hyperplasia;
Immunoenzyme Techniques*;
Immunoradiometric Assay*;
Mass Screening;
Prostate-Specific Antigen;
Prostatic Diseases;
Prostatic Hyperplasia;
Prostatic Neoplasms;
Sensitivity and Specificity
- From:Korean Journal of Urology
1994;35(9):955-961
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Prostate specific antigen (PSA) has become established as the most useful serological marker for monitoring patients with prostate cancer. However, the benefits of serum PSA values are controversial in screening procedures for prostate cancer due to the rather low specificity of PSA test. To determine if different assays yield comparable results, we compared the IMx PSA enzyme immunoassay and the ELSA PSA monoclonal immunoradiometric assay. We analyzed 72 serum specimens from 68 patients with prostatic disease (12 patients with cancer, 47 benign hyperplasia and 9 prostatitis) and 13 from normal controls by both assays. Results from the assays revealed close linear correlation but the ELSA PSA assay yielded values 1.5 times those of the IMx PSA assay In 13 patients with histologically diagnosed benign prostatic hyperplasia, number of patient with PSA value over l0 ng/ml measured by IMx and ELSA assay were 2(15% ) and 4(31%), respectively. We conclude that the proportional bias between assays demonstrates a need for improved standardization of PSA assays.
